Loading...
Loading...
ACRX| Name | Value |
|---|---|
| Revenues | 442.0K |
| Cost of Revenue | 784.0K |
| Gross Profit | -342.0K |
| Operating Expense | 8,653.0K |
| Operating I/L | -8,995.0K |
| Other Income/Expense | 321.0K |
| Interest Income | 711.0K |
| Pretax | -8,674.0K |
| Income Tax Expense | -321.0K |
| Net Income/Loss | -8,353.0K |
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company specializing in the development and commercialization of therapies for acute pain treatment. Its primary product candidate, DSUVIA and DZUVEO, is a 30 mcg sufentanil sublingual tablet designed for moderate-to-severe acute pain. The company also develops ZALVISO, a patient-controlled analgesia system for hospital patients, ARX-02 for cancer breakthrough pain, and 4ARX-03 for mild sedation and pain relief during procedures. Additionally, it is exploring Niyad, a regional anticoagulant, and LTX-608, a nafamostat formulation for antiviral treatment. AcelRx Pharmaceuticals, Inc. generates revenue through the development and commercialization of these pain management therapies.
